Pacira BioSciences, Inc. (PCRX), headquartered in Parsippany, New Jersey, is a leading provider of non-opioid pain management and regenerative health solutions worldwide. The biopharmaceutical company focuses its research, development, and commercialization efforts on providing alternatives to common opioid medications for post-surgical care.
The company is publicly traded on the NASDAQ under the symbol "PCRX" and is most well-known for its flagship product, EXPAREL. EXPAREL (bupivacaine liposome injectable suspension) is an innovative non-opioid medication that provides long-lasting pain relief to patients undergoing surgery. EXPAREL works by numbing the area around the surgical site and providing pain relief for up to 72 hours post-surgery, which is typically when post-surgical pain is at its peak. This significantly decreases, if not eliminates, the need for opioid medications post-surgery, playing a significant role in the fight against the ongoing opioid crisis.
In addition to EXPAREL, Pacira BioSciences has also broadened its product offerings through organic growth and strategic acquisitions, which include the iovera° system, a handheld device for cryoanalgesia, or nerve blocking through targeted freezing. This unique product provides immediate, sustained relief for up to 90 days, offering yet another effective alternative to opioids.
The vision and mission of Pacira BioSciences align with the global need to proactively address the opioid crisis by providing safer, effective alternatives to manage pain. This mission seems even more important considering the current situation where over-prescription of opioids has led to a serious health issue.
Pacira BioSciences' business strategy also includes establishing strong collaborations and partnerships with other healthcare and pharmaceutical companies to extend the reach of their products. By doing so, they make a more significant impact in the medical field, improving patient outcomes and contributing to sustainable healthcare.
The company demonstrates consistent growth and innovation, continually investing in research and development initiatives to ensure they remain at the forefront of non-opioid pain management advancements.
In summary, Pacira BioSciences, Inc. is not just a pharmaceutical company; it is a strong advocate for change in the healthcare industry. Through its commitment to providing non-opioid alternatives for pain management, it makes a significant contribution to the global efforts to combat the opioid crisis. With a clear vision, innovative products, and a strong dedication to improve patient outcomes, Pacira BioSciences is blazing a trail in non-opioid pain management.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Oppenheimer has initiated coverage on Pacira Biosciences (PCRX) with an Outperform rating and a $32 price target. This analyst action follows previous coverage initiations and price adjustments from other firms, highlighting ongoing analyst interest in the pharmaceutical company. Pacira BioSciences specializes in non-opioid pain management and is also developing a gene therapy for osteoarthritis.
The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. are expanding their strategic collaboration to enhance physician education, advocacy, quality improvement, and non-opioid pain management approaches. This partnership, built on three years of engagement, aims to improve patient outcomes through initiatives like supporting the NOPAIN for Veterans Act and reauthorization of the NOPAIN Act. Pacira will also participate in ASA's Center for Perioperative Medicine Corporate Advisory Council and host an interactive Satellite Symposium.
Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to $24.00, and it recently beat EPS estimates with a revenue increase of 6.2% year-over-year.
Truist Financial initiated coverage on Pacira BioSciences (NASDAQ:PCRX) with a "buy" rating and a $30.00 price target, suggesting a 28.81% potential upside. This comes after Pacira BioSciences reported strong quarterly earnings, exceeding analyst estimates with $0.73 EPS and $192.4 million in revenue, a 6.2% increase year-over-year. Despite these positive developments and institutional investor interest, the company maintains a "Hold" consensus rating among analysts, with an average price target of $30.20.
Brokerages have issued a consensus "Hold" rating for Pacira BioSciences (NASDAQ:PCRX), with an average 12-month price target of $29.80 against its current price of $23.00. The company recently surpassed quarterly earnings estimates, reporting $0.73 EPS on $192.4 million in revenue. Institutional investors hold a significant 99.73% of the shares, while an insider recently sold a portion of their holdings.
Empowered Funds LLC significantly increased its stake in Pacira BioSciences (NASDAQ:PCRX) by 21.6% in the first quarter, acquiring 49,171 additional shares, bringing its total holding to 276,776 shares valued at $6.3 million. This increase contributes to institutional investors owning 99.73% of the company's stock. The news follows Pacira's strong Q1 earnings, where it surpassed analyst estimates with $0.73 EPS and a 6.2% year-over-year revenue increase, despite mixed analyst ratings and a recent insider stock sale.
Wedge Capital Management L L P NC has acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX), purchasing 94,554 shares valued at approximately $2.4 million. This acquisition makes Wedge Capital a 0.24% owner of the company, which reports 99.73% institutional ownership. Pacira BioSciences recently exceeded quarterly EPS estimates and saw a 6.2% increase in revenue year-over-year, despite analysts maintaining a consensus "Hold" rating with a price target of $29.80.